LivaNova (NASDAQ:LIVN) Updates FY 2025 Earnings Guidance

LivaNova (NASDAQ:LIVN) issued an update on its FY 2025 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 3.650-3.750 for the period, compared to the consensus earnings per share estimate of 3.630. The company issued revenue guidance of $1.3 billion-$1.3 billion, compared to the consensus revenue estimate of $1.3 billion.

LivaNova Trading Up 4.3 %

NASDAQ LIVN opened at $49.50 on Tuesday. LivaNova has a 1-year low of $43.15 and a 1-year high of $64.47. The stock has a 50-day moving average of $47.94 and a 200-day moving average of $49.64. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46. The firm has a market cap of $2.69 billion, a PE ratio of 117.86 and a beta of 1.00.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on LIVN shares. Mizuho cut their price target on LivaNova from $80.00 to $70.00 and set an “outperform” rating on the stock in a research note on Thursday, October 31st. StockNews.com raised LivaNova from a “buy” rating to a “strong-buy” rating in a research report on Friday, February 14th. Robert W. Baird upped their price objective on LivaNova from $66.00 to $72.00 and gave the company an “outperform” rating in a research report on Thursday, October 31st. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $75.00 price objective on shares of LivaNova in a research report on Tuesday, January 28th. One analyst has rated the stock with a hold rating, five have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $69.17.

Insider Activity

In other news, Director Francesco Bianchi sold 1,250 shares of the company’s stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $50.99, for a total value of $63,737.50. Following the completion of the sale, the director now directly owns 7,522 shares in the company, valued at $383,546.78. This represents a 14.25 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Insiders own 0.27% of the company’s stock.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.